RU2002128733A - МОДУЛЯТОРЫ PPARγ - Google Patents
МОДУЛЯТОРЫ PPARγInfo
- Publication number
- RU2002128733A RU2002128733A RU2002128733/04A RU2002128733A RU2002128733A RU 2002128733 A RU2002128733 A RU 2002128733A RU 2002128733/04 A RU2002128733/04 A RU 2002128733/04A RU 2002128733 A RU2002128733 A RU 2002128733A RU 2002128733 A RU2002128733 A RU 2002128733A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- nitrophenyl
- carboxamide
- chloro
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/58—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/20—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/24—Derivatives of thiourea containing any of the groups, X being a hetero atom, Y being any atom
- C07C335/26—Y being a hydrogen or a carbon atom, e.g. benzoylthioureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/24—Derivatives of thiourea containing any of the groups, X being a hetero atom, Y being any atom
- C07C335/28—Y being a hetero atom, e.g. thiobiuret
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/42—Benzene-sulfonamido pyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C07D263/50—Benzene-sulfonamido oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/28—Nitrogen atoms
- C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/72—Ethanonaphthalenes; Hydrogenated ethanonaphthalenes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (22)
1. Соединение следующей формулы (I) или его фармакологически приемлемая соль:
где А означает фенильную, нафтильную, аценафтенильную, пиридильную, хинолильную, изохинолильную, пиримидинильную, фурильную, бензофурильную, пиранильную, хроменильную, тиенильную, бензотиенильную, пирролильную, индолильную, изоиндолильную, имидазолильную, пиразолильную, пиридазинильную, пиразинильную, оксазолильную, изоксазолильную, бензоксазолильную, бензизоксазолильную, тиазолильную, изотиазолильную, бензотиазолильную, бензизотиазолильную или бифенильную группу (указанная группа А необязательно замещена одним, двумя или более заместителями, имеющими одинаковые или разные значения, которые выбирают из приведенной ниже группы заместителей α);
В означает арильную, циклоалкильную или гетероциклическую группу (указанная группа В необязательно замещена одним, двумя или более заместителями, имеющими одинаковые или разные значения, которые выбирают из приведенных ниже группы заместителей α и β);
Х означает связь, атом кислорода, атом серы, группу CH2, CO, NH, SO2NH, NHSO2, CONH, NHCO или OCH2;
n означает 0 или 1;
группа заместителей а включает С1-С20 алкильную группу, нитрогруппу, цианогруппу, карбоксильную группу, карбокси-С2-С7 алкильную группу, С2-С7 алкилоксикарбонильную группу, С3-С15 алкилоксикарбонилалкильную группу, аминогруппу (указанная аминогруппа необязательно замещена одной или двумя C1-C6 алкильными группами, имеющими одинаковые или разные значения, или C6-C3 алкенильной группой), гидроксильную группу (указанная гидроксильная группа необязательно замещена C1-Cg алкильной группой или C1-C6 галогеналкильной группой) и меркаптогруппу (указанная меркаптогруппа необязательно замещена C1-C6 алкильной группой);
группа заместителей β включает атом галогена, сульфонамидную группу, C1-C6 алкилсульфонамидную группу, амидиноаминосульфонильную группу или фенильную группу.
2. Соединение формулы (I) или его фармакологически приемлемая соль по п.1, где А означает тиазолильную группу.
3. Соединение, выбираемое из следующих соединений или их фармакологически премлемых солей:
N-[4-(трет-бутилоксикарбониламинофенил)]-(2-хлор-5-нитрофенил)карбоксамид;
N-[3-карбоэтокси-4,5,6,7-тетрагидробензо[Ь]тиофен-2-ил]-(2-хлор-5-нитрофенил)карбоксамид;
N-(3-метилбензимидазол-2-ил)-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(трет-бутоксикарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(6-ацетокси-2,5,7,8-тетраметил-4-оксохроман-2-илметокси)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(6-гидрокси-2,5,7,8-тетраметил-4-оксохроман-2-илметокси)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(амидиноаминосульфонил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(бутиламинокарбониламиносульфонил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-(5-фенил[1,3,4]тиадиазол-2-ил)-(2-хлор-5-нитрофенил)карбоксамид;
N-(4-ацетиламинофенил)-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(4-ацетиламинофенил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-(4-этансульфониламинофенил)-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(4-ацетоксифенил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-(4-метансульфониламинофенил)-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(пирролидинилсульфонил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(морфолин-4-илсульфонил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[3-(пирролидинилсульфонил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-(4-ацетилфенил)-(2-хлор-5-нитрофенил)карбоксамид;
N-(3-ацетилфенил)-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(2-трет-бутоксикарбониламиноэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
0,2 гидрат гидрохлорида N-[4-(2-аминоэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамида;
N-[4-[4-(морфолин-4-ил)фенил]аминосульфонил]фенил-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(4-ацетилпиперазин-1-ил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(4-бензоилпиперазин-1-ил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[[4-[4-(имидазол-1-ил)фенил]аминосульфонил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(4-трет-бутоксикарбониламинофенил)тиазол-2-ил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(пиридин-3-илкарбонил)пиперазин-1-ил]фенил]-2-(хлор-5-нитрофенил)карбоксамид;
N-[4-(2-гидроксиэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[[3-[4-(имидазол-1-ил)фенил]аминокарбонил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(3-трет-бутоксикарбониламинофенил)тиазол-2-ил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(метиламинотиокарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(2,2,2-трифтор-1-гидрокси-1-трифторметилэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(1-гидроксиэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[3-(1-гидроксиэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(фениламинокарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(аминокарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(этоксикарбониламинокарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-[(3-фторфенил)аминотиокарбониламино]фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-[(3-метоксифенил)аминокарбониламино]фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(бензиламинокарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-[(2,4-дифторфенил)аминокарбониламино]фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(бензоиламинотиокарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(этоксикарбониламинотиокарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(фениламинотиокарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(2-нитрофениламинокарбониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-[(пиридин-3-ил)аминотиокарбониламино]фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[(пиридин-3-ил)аминотиокарбониламино]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-[(пиридин-4-ил)аминотиокарбониламино]фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[(пиридин-4-ил)аминотиокарбониламино]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[(6-трет-бутоксикарбониламино)бензотиазол-2-ил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(4-метансульфониламинофенил)тиазол-2-ил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(4-ацетиламинофенил)тиазол-2-ил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[(4-аминокарбонил)пиперазин-1-ил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(2-ацетиламинотиазол-4-ил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[3-(2-ацетиламинотиазол-4-ил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(2-аминоэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(2-фениламинокарбониламиноэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(2-фениламинотиокарбониламиноэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(2-аминокарбониламиноэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(2-фенилкарбониламинотиокарбониламиноэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(2-этоксикарбониламинотиокарбониламиноэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[2-(пиридин-3-ил)аминотиокарбониламиноэтил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[3-(2-гидроксиэтил)фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-[4-(N,N-диэтансульфониламино)фенил]фенил]-(2-хлор-5-нитрофенил)карбоксамид;
N-[4-(3-ацетиламинофенил)тиазол-2-ил]-(2-хлор-5-нитрофенил)карбоксамид;
N-(6-ацетиламинобензотиазол-2-ил)-(2-хлор-5-нитрофенил)карбоксамид; и
N-(6-аминокарбониламинобензотиазол-2-ил)-(2-хлор-5-нитрофенил)карбоксамид.
4. Фармацевтическая композиция, включающая фармацевтически приемлемый разбавитель или носитель и соединение или его фармакологически приемлемую соль по любому из пп.1-3.
5. Соединение или его фармакологически приемлемая соль по любому из пп.1-3 для применения в качестве средства, ингибирующего дифференцировку адипоцитов в костном мозге.
6. Соединение или его фармакологически приемлемая соль по любому из пп.1-3 для применения в качестве средства, усиливающего или восстанавливающего функцию остеогенеза.
7. Соединение или его фармакологически приемлемая соль по любому из пп.1-3 для применения в качестве средства для лечения или профилактики остеопороза.
8. Соединение или его фармакологически приемлемая соль по любому из пп.1-3 для применения в качестве средства для лечения или профилактики старческого остеопороза, постклимактерического остеопороза или остеопороза, являющегося следствием прекращения приема лекарственных средств.
9. Соединение или его фармакологически приемлемая соль по любому из пп.1-3 для применения в качестве средства, обладающего моделирующей PPAR γ активностью.
10. Соединение или его фармакологически приемлемая соль по любому из пп.1-3 для применения в качестве средства, снижающего уровень сахара в крови.
11. Соединение или его фармакологически приемлемая соль по любому из пп.1-3 для применения в качестве средства для лечения или профилактики сахарного диабета.
12. Соединение или его фармакологически приемлемая соль по любому из пп.1-3 для применения в качестве средства для лечения или профилактики сахарного диабета типа I, сахарного диабета типа II, нарушения глюкозного обмена, диабетической невропатии или вызываемых диабетом осложнений.
13. Соединение или его фармакологически приемлемая соль по любому из пп.1-3 для применения в качестве средства для лечения или профилактики переломов, неполного остеогенеза, рахита, старческого артроза, ожирения, истощения, артериосклероза, нарушения липидного обмена, панкреатита, аутоиммунных заболеваний, гиперурикемии, лейкоза, функциональных нарушений родственных ретиноидам рецепторов, дисфункции печени, анемии, злокачественных опухолей, воспалений, базедовой болезни, заболеваний сердца, болезни Альцгеймера, нарушений питания, гипертензии или заболеваний почек.
14. Средство, ингибирующее дифференцировку адипоцитов в костном мозге, включающее соединение или его фармакологически приемлемую соль по любому из пп.1-3.
15. Средство, усиливающее или восстанавливающее функцию остеогенеза, включающее соединение или его фармакологически приемлемую соль по любому из пп.1-3.
16. Средство для лечения или профилактики остеопороза, включающее соединение или его фармакологически приемлемую соль по любому из пп.1-3.
17. Средство для лечения или профилактики старческого остеопороза, постклимактерического остеопороза или остеопороза, являющегося следствием прекращения приема лекарственных средств, включающее соединение или его фармакологически приемлемую соль по любому из пп.1-3.
18. Средство, обладающее модулирующей PPARγ активностью, включающее соединение или его фармакологически приемлемую соль по любому из пп.1-3.
19. Средство, снижающее уровень сахара в крови, включающее соединение или его фармакологически приемлемую соль по любому из пп.1-3.
20. Средство, предназначенное для лечения или профилактики сахарного диабета, включающее соединение или его фармакологически приемлемую соль по любому из пп.1-3.
21. Средство для лечения или профилактики сахарного диабета типа I, сахарного диабета типа II, нарушения глюкозного обмена, диабетической невропатии или вызываемых диабетом осложнений, включающее соединение или его фармацевтически приемлемую соль по любому из пп.1-3.
22. Средство для лечения или профилактики переломов, неполного остеогенеза, рахита, старческого артроза, ожирения, истощения, артериосклероза, нарушения липидного обмена, панкреатита, аутоиммунных заболеваний, гиперурикемии, лейкоза, функциональных нарушений родственных ретиноидам рецепторов, дисфункции печени, анемии, злокачественных опухолей, воспалений, базедовой болезни, заболеваний сердца, болезни Альцгеймера, нарушений питания, гипертензии или заболеваний почек, включающее соединение или его фармакологически приемлемую соль по любому из пп.1-3.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-129565 | 2000-04-28 | ||
JP2000129565 | 2000-04-28 | ||
JP2001060366 | 2001-03-05 | ||
JP2001-060366 | 2001-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2002128733A true RU2002128733A (ru) | 2004-03-10 |
Family
ID=26591117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002128733/04A RU2002128733A (ru) | 2000-04-28 | 2001-04-26 | МОДУЛЯТОРЫ PPARγ |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030134859A1 (ru) |
EP (1) | EP1277729A4 (ru) |
JP (1) | JP2002332266A (ru) |
KR (1) | KR20020089493A (ru) |
CN (1) | CN1440383A (ru) |
AU (1) | AU2001252612A1 (ru) |
BR (1) | BR0110428A (ru) |
CA (1) | CA2407587A1 (ru) |
CZ (1) | CZ20023562A3 (ru) |
HK (1) | HK1049325A1 (ru) |
HU (1) | HUP0301146A3 (ru) |
IL (1) | IL152451A0 (ru) |
MX (1) | MXPA02010651A (ru) |
NO (1) | NO20025142L (ru) |
PL (1) | PL357678A1 (ru) |
RU (1) | RU2002128733A (ru) |
WO (1) | WO2001083427A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2442773C2 (ru) * | 2005-12-09 | 2012-02-20 | Зольвай Фармасьютиклз Гмбх | Новые n-сульфамоилпиперидинамиды, предназначенные для профилактики или лечения ожирения и родственных патологических состояний |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
JP4083422B2 (ja) * | 2000-12-22 | 2008-04-30 | 石原産業株式会社 | アニリン誘導体またはその塩ならびにそれらを含有するサイトカイン産生抑制剤 |
CA2432713C (en) * | 2000-12-22 | 2009-10-27 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
IL159511A0 (en) * | 2001-07-20 | 2004-06-01 | Juvantia Pharma Ltd Oy | Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
AU2002322585A1 (en) * | 2001-07-20 | 2003-03-03 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
WO2003013516A1 (en) * | 2001-08-10 | 2003-02-20 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
WO2003033494A1 (fr) * | 2001-10-17 | 2003-04-24 | Sankyo Company, Limited | Derive de benzimidazole |
WO2003035602A1 (fr) * | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Modulateurs lipidiques |
AU2002367023A1 (en) * | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
ES2295672T3 (es) * | 2002-08-07 | 2008-04-16 | Neuraxon Inc. | Compuestos de aminobenzotiazol con actividad inhibitoria de la oxido nitrico sintasa (nos). |
JP2005104951A (ja) * | 2003-01-17 | 2005-04-21 | Kirin Brewery Co Ltd | 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品 |
US7125901B2 (en) * | 2003-01-27 | 2006-10-24 | Astellas Pharma Inc. | Thiazole derivatives |
EP1631558A1 (en) * | 2003-05-21 | 2006-03-08 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
US7173030B2 (en) | 2003-05-21 | 2007-02-06 | Biovitrum Ab | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
CA2528785A1 (en) * | 2003-06-20 | 2005-01-06 | Matthias Heinrich Nettekoven | 2-amidobenzothiazoles as cb1 receptor inverse agonists |
ATE492278T1 (de) * | 2003-07-23 | 2011-01-15 | Synta Pharmaceuticals Corp | Verbindungen gegen entzündungen und immun- relevante verwendungen |
FR2858321B1 (fr) * | 2003-07-28 | 2006-01-20 | Servier Lab | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN100554249C (zh) * | 2003-08-29 | 2009-10-28 | 三井化学株式会社 | 农园艺用杀虫剂及其使用方法 |
EP1535612B1 (en) * | 2003-11-28 | 2006-09-13 | Merck Sante | Treatment for hyperuricemia |
AU2004299198A1 (en) * | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivates |
US20070149606A1 (en) * | 2003-12-26 | 2007-06-28 | Daiichi Pharmaceutical Co.,Ltd. | Process for producing phenylacetic acid derivative |
KR100904360B1 (ko) * | 2004-01-28 | 2009-06-23 | 미쓰이 가가쿠 가부시키가이샤 | 아미드 유도체 및 그 제조 방법 및 그의 살충제로서의 사용방법 |
WO2005087219A1 (ja) * | 2004-03-10 | 2005-09-22 | Research Foundation Itsuu Laboratory | 記憶固定促進剤 |
CA2558135C (en) * | 2004-03-18 | 2012-08-14 | R-Tech Ueno, Ltd. | Aqueous composition comprising thiazole derivative |
UA90864C2 (en) * | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
MX2007003332A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
BRPI0515488A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de heterocìclicos e seu uso como agentes terapêuticos |
TW200626139A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
EP1814551A2 (en) | 2004-09-20 | 2007-08-08 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
TW200626572A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
WO2006034440A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
GB0421908D0 (en) * | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
JP2008019169A (ja) * | 2004-10-25 | 2008-01-31 | Osaka Univ | 新規ppar調節剤およびそのスクリーニング方法 |
JP4221383B2 (ja) * | 2005-02-10 | 2009-02-12 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
US7767682B2 (en) | 2005-03-03 | 2010-08-03 | Glaxosmithkline Llc | Medicaments |
EP1858512A4 (en) * | 2005-03-14 | 2009-08-05 | Immunomedics Inc | METHODS OF TREATING CANCER USING PPAR-GAMMA ANTAGONISTS |
EP2540296A1 (en) | 2005-06-03 | 2013-01-02 | Xenon Pharmaceuticals Inc. | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
EP1911751A4 (en) | 2005-06-21 | 2010-10-20 | Mitsui Chemicals Agro Inc | AMIDE DERIVATIVE AND PESTICIDE CONTAINING SUCH A COMPOUND |
DE602006018172D1 (de) * | 2005-10-06 | 2010-12-23 | Sanofi Aventis | Cyclische n-ä1,3,4ü-thiadiazol-2-yl-benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel |
JP2009510147A (ja) * | 2005-10-06 | 2009-03-12 | サノフィ−アベンティス | N−[1,3,4]−チアジアゾール−2−イル−ベンゼンスルホンアミド類、それらの製造方法及び医薬品としてのそれらの使用 |
NZ567204A (en) | 2005-10-06 | 2010-06-25 | Sanofi Aventis | Bicyclic aryl-sulphonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation and their use as pharmaceuticals |
CN101096363B (zh) * | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
US7994338B2 (en) | 2006-08-16 | 2011-08-09 | The J. David Gladstone Institutes | Small molecule inhibitors of kynurenine-3-monooxygenase |
EP2054056A4 (en) * | 2006-08-16 | 2010-08-25 | J David Gladstone Inst A Testa | SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE |
US20110039893A1 (en) * | 2006-10-11 | 2011-02-17 | Takeda Pharmaceutical Company Limited | Gsk-3beta inhibitor |
US20090317360A1 (en) * | 2007-06-12 | 2009-12-24 | Genelabs Technologies, Inc. | Anti-viral inhibitors and methods of use |
EP2338059B1 (en) * | 2008-09-23 | 2015-04-08 | WisTa Laboratories Ltd. | Ligands for aggregated tau molecules |
DE102008049675A1 (de) | 2008-09-30 | 2010-04-01 | Markus Dr. Heinrich | Verfahren zur Herstellung von 3-Aminobiphenylen |
GB0907601D0 (en) * | 2009-05-01 | 2009-06-10 | Equateq Ltd | Novel methods |
TW201103904A (en) * | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
US20130158035A1 (en) * | 2010-08-24 | 2013-06-20 | Brigham Young University | Antimetastatic compounds |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
JP5930205B2 (ja) | 2010-08-26 | 2016-06-08 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化促進剤 |
WO2012121168A1 (ja) * | 2011-03-04 | 2012-09-13 | 国立大学法人京都大学 | キナーゼ阻害剤 |
EP2808383B1 (en) | 2012-01-27 | 2018-07-25 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell |
WO2014136519A1 (ja) | 2013-03-08 | 2014-09-12 | 国立大学法人京都大学 | Egf受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 |
EP3150705B1 (en) | 2014-05-30 | 2019-05-15 | Kyoto University | Method for inducing myocardial differentiation of pluripotent stem cells using low-molecular compound |
JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および/またはリポジストロフィーの処置のための方法 |
TW201643143A (zh) * | 2015-03-13 | 2016-12-16 | 國立大學法人北海道大學 | 抑制氧化壓迫引發的神經細胞死亡之化合物 |
KR101815193B1 (ko) * | 2015-12-29 | 2018-01-30 | (주)스파크바이오파마 | PPARγ 인산화 저해제 및 이를 포함하는 약학적 조성물 |
KR20190065252A (ko) * | 2016-08-18 | 2019-06-11 | 인테크린 테라퓨틱스, 아이엔씨. | 골 질환 치료용 PPARγ 작용제 |
BR112019020485A2 (pt) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | Agonista ppary para tratamento de paralisia supranuclear progressiva |
EP3498694A1 (en) | 2017-12-12 | 2019-06-19 | Medibiofarma, S.L. | New benzamide derivatives as ppar-gamma modulators |
CN109730999B (zh) * | 2018-12-28 | 2021-12-24 | 中山大学 | 噻唑苯甲酰胺衍生在制备抗骨质疏松、抗骨关节炎药物中的应用 |
CN110156729B (zh) * | 2019-05-14 | 2022-12-06 | 浙江大学 | 一种苯基哌嗪类ube2f小分子抑制剂及其合成方法 |
KR102337399B1 (ko) * | 2019-10-02 | 2021-12-09 | 주식회사 클로소사이언스 | 항노화 유전자 klotho의 발현을 유도하는 화합물 및 이의 용도 |
CN112812077B (zh) * | 2019-11-18 | 2023-08-22 | 中国科学院上海药物研究所 | 苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
CN113831301B (zh) * | 2020-06-08 | 2023-06-06 | 沈阳药科大学 | 苯并噻唑类衍生物及其用途 |
WO2022211574A1 (ko) * | 2021-04-01 | 2022-10-06 | 주식회사 클로소사이언스 | 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물 |
CA3214952A1 (en) * | 2021-04-09 | 2022-10-13 | Silvana Marcel LEIT DE MORADEI | Cbl-b modulators and uses thereof |
CN115232030A (zh) * | 2021-04-23 | 2022-10-25 | 中国医学科学院药物研究所 | 芳基脲类化合物及其制法和药物用途 |
WO2023172846A1 (en) * | 2022-03-08 | 2023-09-14 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
WO2023172845A1 (en) * | 2022-03-08 | 2023-09-14 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
CN115093389A (zh) * | 2022-05-31 | 2022-09-23 | 广州医科大学 | 6-酰胺色满-3-甲酰胺衍生物及其制备方法和应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2754209A (en) * | 1952-06-10 | 1956-07-10 | Azoplate Corp | Light-sensitive para quinone diazides for making printing plates |
DE1642224B2 (de) * | 1967-04-28 | 1976-04-29 | Basf Ag, 6700 Ludwigshafen | Verwendung von substituierten benzoesaeureaniliden zur bekaempfung von pilzen aus der klasse der basidiomyceten |
US5449691A (en) * | 1991-12-31 | 1995-09-12 | Sterling Winthrop Inc. | 3,4-disubstituted anilines-immunomodulating agents |
US5516774A (en) * | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US7115728B1 (en) * | 1995-01-30 | 2006-10-03 | Ligand Pharmaceutical Incorporated | Human peroxisome proliferator activated receptor γ |
AU5524896A (en) * | 1995-03-20 | 1996-10-08 | Institut Pasteur De Lille | Modulators of ob gene and screening methods therefor |
US5939442A (en) * | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
AU7074496A (en) * | 1995-09-18 | 1997-04-09 | Ligand Pharmaceuticals Incorporated | Ppar gamma antagonists for treating obesity |
WO1998005331A2 (en) * | 1996-08-02 | 1998-02-12 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
DK0993831T3 (da) * | 1997-02-07 | 2008-03-25 | Emisphere Tech Inc | Forbindelser og præparater til tilförsel af aktive stoffer |
ES2317688T3 (es) * | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
EP1071429B1 (en) * | 1998-04-17 | 2002-01-30 | Trustees Of Tufts College | Map kinase inhibitors in the treatment of disorders caused by tnf-alpha induced lipolysis |
WO2000000194A1 (en) * | 1998-06-27 | 2000-01-06 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
GB9824614D0 (en) * | 1998-11-11 | 1999-01-06 | Glaxo Group Ltd | Chemical compounds |
EP1161412A1 (en) * | 1999-03-16 | 2001-12-12 | Glaxo Group Limited | Nuclear receptor arylating compounds |
-
2001
- 2001-04-26 IL IL15245101A patent/IL152451A0/xx unknown
- 2001-04-26 BR BR0110428-4A patent/BR0110428A/pt not_active Application Discontinuation
- 2001-04-26 PL PL01357678A patent/PL357678A1/xx not_active Application Discontinuation
- 2001-04-26 WO PCT/JP2001/003655 patent/WO2001083427A1/ja not_active Application Discontinuation
- 2001-04-26 EP EP01925984A patent/EP1277729A4/en not_active Withdrawn
- 2001-04-26 CN CN01812056A patent/CN1440383A/zh active Pending
- 2001-04-26 RU RU2002128733/04A patent/RU2002128733A/ru unknown
- 2001-04-26 CA CA002407587A patent/CA2407587A1/en not_active Abandoned
- 2001-04-26 AU AU2001252612A patent/AU2001252612A1/en not_active Abandoned
- 2001-04-26 MX MXPA02010651A patent/MXPA02010651A/es unknown
- 2001-04-26 CZ CZ20023562A patent/CZ20023562A3/cs unknown
- 2001-04-26 KR KR1020027013937A patent/KR20020089493A/ko not_active Application Discontinuation
- 2001-04-26 HU HU0301146A patent/HUP0301146A3/hu unknown
- 2001-04-27 JP JP2001130983A patent/JP2002332266A/ja active Pending
-
2002
- 2002-10-23 US US10/278,387 patent/US20030134859A1/en not_active Abandoned
- 2002-10-25 NO NO20025142A patent/NO20025142L/no not_active Application Discontinuation
-
2003
- 2003-02-27 HK HK03101447.4A patent/HK1049325A1/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2442773C2 (ru) * | 2005-12-09 | 2012-02-20 | Зольвай Фармасьютиклз Гмбх | Новые n-сульфамоилпиперидинамиды, предназначенные для профилактики или лечения ожирения и родственных патологических состояний |
Also Published As
Publication number | Publication date |
---|---|
CN1440383A (zh) | 2003-09-03 |
EP1277729A1 (en) | 2003-01-22 |
US20030134859A1 (en) | 2003-07-17 |
JP2002332266A (ja) | 2002-11-22 |
AU2001252612A1 (en) | 2001-11-12 |
PL357678A1 (en) | 2004-07-26 |
HUP0301146A2 (hu) | 2003-08-28 |
KR20020089493A (ko) | 2002-11-29 |
WO2001083427A1 (fr) | 2001-11-08 |
HUP0301146A3 (en) | 2004-08-30 |
CA2407587A1 (en) | 2001-11-08 |
MXPA02010651A (es) | 2003-03-10 |
HK1049325A1 (zh) | 2003-05-09 |
NO20025142L (no) | 2002-12-27 |
NO20025142D0 (no) | 2002-10-25 |
CZ20023562A3 (cs) | 2003-03-12 |
BR0110428A (pt) | 2003-06-17 |
IL152451A0 (en) | 2003-05-29 |
EP1277729A4 (en) | 2005-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002128733A (ru) | МОДУЛЯТОРЫ PPARγ | |
CA2449999A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
RU2004122407A (ru) | Амидные производные в качестве активаторов gk | |
JP2004517080A5 (ru) | ||
RU2419624C2 (ru) | Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
JP5860427B2 (ja) | ヒトプロテインチロシンホスファターゼβ阻害剤および使用法 | |
ES2534392T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
RU2006104697A (ru) | Лекарственное средство для лечения пигментации кожи | |
RU2006107653A (ru) | Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли | |
RU2008108984A (ru) | Терапевтический агент от диабета | |
JP2008519761A5 (ru) | ||
JP2006077019A5 (ru) | ||
CA2443952A1 (en) | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | |
CA2435067A1 (en) | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | |
JP2005514334A5 (ru) | ||
RU2011134631A (ru) | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний | |
CA2485850A1 (en) | 8-azaprostaglandin analogs as agents for lowering intraocular pressure | |
RU2005121667A (ru) | 5-замещенные пиразиновые или пиридиновые активаторы глюкокиназы | |
JP2007502806A5 (ru) | ||
RU96111013A (ru) | ЗАМЕЩЕННЫЕ N-(ИНДОЛ-2-КАРБОНИЛ)β-АЛАНИМАМИДЫ И ИХ ПРОИЗВОДНЫЕ, СПОСОБ ЛЕЧЕНИЯ ГЛИКОГЕНФОСФОРИЛАЗОЗАВИСИМЫХ ЗАБОЛЕВАНИЙ, СПОСОБ ПРЕДУПРЕЖДЕНИЯ ИШЕМИЧЕСКОГО ПОВРЕЖДЕНИЯ МИОКАРДА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
JP2003528872A5 (ru) | ||
RU99105567A (ru) | Производные пропионовой кислоты и их использование | |
RU2004100839A (ru) | Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов | |
RU2004126936A (ru) | Производные хинолина в качестве антагонистов npv | |
RU2001127082A (ru) | Производные аминов |